Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $8.48 in the prior trading day, Zymeworks BC Inc (NASDAQ: ZYME) closed at $8.43, down -0.59%. In other words, the price has decreased by -$0.59 from its previous closing price. On the day, 1.56 million shares were traded. ZYME stock price reached its highest trading level at $9.31 during the session, while it also had its lowest trading level at $8.42.
Ratios:
Our goal is to gain a better understanding of ZYME by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.92 and its Current Ratio is at 6.92. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On January 04, 2023, H.C. Wainwright reiterated its Neutral rating and also upped its target price recommendation from $10 to $8.
Jefferies Upgraded its Hold to Buy on December 20, 2022, whereas the target price for the stock was revised from $7.70 to $11.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 08 ’24 when Galbraith Kenneth sold 5,706 shares for $11.22 per share. The transaction valued at 63,996 led to the insider holds 23,762 shares of the business.
Moore Paul Andrew sold 2,339 shares of ZYME for $26,233 on Jan 08 ’24. The Chief Scientific Officer now owns 7,367 shares after completing the transaction at $11.22 per share. On Jan 08 ’24, another insider, Astle Christopher, who serves as the SVP & Chief Financial Officer of the company, sold 1,431 shares for $11.22 each. As a result, the insider received 16,050 and left with 6,503 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 596042304 and an Enterprise Value of 276242208. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.91 while its Price-to-Book (P/B) ratio in mrq is 1.37. Its current Enterprise Value per Revenue stands at 5.474 whereas that against EBITDA is -1.943.
Stock Price History:
Over the past 52 weeks, ZYME has reached a high of $13.14, while it has fallen to a 52-week low of $6.01. The 50-Day Moving Average of the stock is -7.90%, while the 200-Day Moving Average is calculated to be -6.33%.
Shares Statistics:
The stock has traded on average 636.84K shares per day over the past 3-months and 644110 shares per day over the last 10 days, according to various share statistics. A total of 70.12M shares are outstanding, with a floating share count of 66.07M. Insiders hold about 7.30% of the company’s shares, while institutions hold 95.34% stake in the company. Shares short for ZYME as of 1715731200 were 4033706 with a Short Ratio of 6.33, compared to 1713139200 on 5050020. Therefore, it implies a Short% of Shares Outstanding of 4033706 and a Short% of Float of 6.4799999999999995.
Earnings Estimates
The market rating for Zymeworks BC Inc (ZYME) is a result of the insights provided by 7.0 analysts actively involved in the assessment.On average, analysts expect EPS of -$0.19 for the current quarter, with a high estimate of $1.13 and a low estimate of -$0.48, while EPS last year was -$0.76. The consensus estimate for the next quarter is -$0.46, with high estimates of -$0.35 and low estimates of -$0.69.
Analysts are recommending an EPS of between -$0.22 and -$1.72 for the fiscal current year, implying an average EPS of -$1.06. EPS for the following year is -$1.14, with 7.0 analysts recommending between $0.5 and -$2.03.
Revenue Estimates
7 analysts predict $29.38M in revenue for the current quarter. It ranges from a high estimate of $134.2M to a low estimate of $6.79M. As of the current estimate, Zymeworks BC Inc’s year-ago sales were $12.36MFor the next quarter, 7 analysts are estimating revenue of $12.22M. There is a high estimate of $16.01M for the next quarter, whereas the lowest estimate is $4.2M.
A total of 7 analysts have provided revenue estimates for ZYME’s current fiscal year. The highest revenue estimate was $165M, while the lowest revenue estimate was $40.38M, resulting in an average revenue estimate of $95.55M. In the same quarter a year ago, actual revenue was $76.01MBased on 7 analysts’ estimates, the company’s revenue will be $118.05M in the next fiscal year. The high estimate is $272.63M and the low estimate is $51.35M.
